abrdn Life Sciences Investors (abrdn Life Sciences Investors) EV-to-Revenue : 15.08 (As of Apr. 26, 2024)

View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, abrdn Life Sciences Investors's enterprise value is $354.74 Mil. abrdn Life Sciences Investors's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $23.52 Mil. Therefore, abrdn Life Sciences Investors's EV-to-Revenue for today is 15.08.

The historical rank and industry rank for abrdn Life Sciences Investors's EV-to-Revenue or its related term are showing as below:

HQL' s EV-to-Revenue Range Over the Past 10 Years
Min: -6.02 Med: 5.55 Max: 17.03
Current: 15.08

During the past 7 years, the highest EV-to-Revenue of abrdn Life Sciences Investors was 17.03. The lowest was -6.02. And the median was 5.55.

HQL's EV-to-Revenue is ranked worse than
65.65% of 1444 companies
in the Asset Management industry
Industry Median: 9.23 vs HQL: 15.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), abrdn Life Sciences Investors's stock price is $12.97. abrdn Life Sciences Investors's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.93. Therefore, abrdn Life Sciences Investors's PS Ratio for today is 13.95.

abrdn Life Sciences Investors EV-to-Revenue Historical Data

The historical data trend for abrdn Life Sciences Investors's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors EV-to-Revenue Chart

abrdn Life Sciences Investors Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EV-to-Revenue

Get a 7-Day Free Trial

-5.03

3.38

7.81

-3.40

14.20

abrdn Life Sciences Investors Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-Revenue	Get a 7-Day Free Trial								7.81	-	-3.40	-	14.20

Competitive Comparison of abrdn Life Sciences Investors's EV-to-Revenue

For the Asset Management subindustry, abrdn Life Sciences Investors's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

abrdn Life Sciences Investors's EV-to-Revenue Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's EV-to-Revenue falls into.

abrdn Life Sciences Investors EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

abrdn Life Sciences Investors's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	354.736	/	23.523
	=	15.08

abrdn Life Sciences Investors's current Enterprise Value is $354.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $23.52 Mil.

abrdn Life Sciences Investors (NYSE:HQL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

abrdn Life Sciences Investors's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	12.97	/	0.93
	=	13.95

abrdn Life Sciences Investors's share price for today is $12.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was $0.93.

abrdn Life Sciences Investors EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103

Website

https://www.abrdnhql.com

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.

Executives

Todd Reit	director	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher	director	600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino	director	C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor	other: Director of Adviser	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc.	other: Adviser	1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar	officer: VP and Chief Legal Officer	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols	other: Director of Adviser	1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard	officer: President	ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy	officer: Secretary and Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari	officer: Treasurer and CFO	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson	officer: Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina	officer: Chief Compliance Officer & VP	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022